Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.

about

Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.

Item

http://www.wikidata.org/entity/Q48250743

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Reduced-intensity conditioning ...... y after autologous transplant.

@en

Reduced-intensity conditioning ...... y after autologous transplant.

@nl

type

Item

label

Reduced-intensity conditioning ...... y after autologous transplant.

@en

Reduced-intensity conditioning ...... y after autologous transplant.

@nl

prefLabel

Reduced-intensity conditioning ...... y after autologous transplant.

@en

Reduced-intensity conditioning ...... y after autologous transplant.

@nl

P1476

Reduced-intensity conditioning ...... ly after autologous transplant

@en

P2093

Alexandros Kanellopoulos

http://www.w3.org/2001/XMLSchema#string

Bhuvan Kishore

http://www.w3.org/2001/XMLSchema#string

Evgenia Xenou

http://www.w3.org/2001/XMLSchema#string

Julie Suhr

http://www.w3.org/2001/XMLSchema#string

Kate Randall

http://www.w3.org/2001/XMLSchema#string

Kathy Holder

http://www.w3.org/2001/XMLSchema#string

Lynda Baker

http://www.w3.org/2001/XMLSchema#string

Lynn Ryan

http://www.w3.org/2001/XMLSchema#string

Maria Kaparou

http://www.w3.org/2001/XMLSchema#string

Richard Lovell

http://www.w3.org/2001/XMLSchema#string

P2860

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Durable remission with salvage second autotransplants in patients with multiple myeloma.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Lenalidomide after stem-cell transplantation for multiple myeloma

International uniform response criteria for multiple myeloma.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

P304

300-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12917

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emmanouil Nikolousis

P577

2017-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28632322

http://www.w3.org/2001/XMLSchema#string